BR0107764A - Composições de peptìdeo cìclico nasalmente administráveis - Google Patents

Composições de peptìdeo cìclico nasalmente administráveis

Info

Publication number
BR0107764A
BR0107764A BR0107764-3A BR0107764A BR0107764A BR 0107764 A BR0107764 A BR 0107764A BR 0107764 A BR0107764 A BR 0107764A BR 0107764 A BR0107764 A BR 0107764A
Authority
BR
Brazil
Prior art keywords
vehicle
cyclic peptide
nasally
analogs
powder
Prior art date
Application number
BR0107764-3A
Other languages
English (en)
Inventor
Ikuo Horii
Kazuko Kobayashi
Nobuo Shimma
Akira Ianagawa
Original Assignee
Basilea Pharmaceutica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica Ag filed Critical Basilea Pharmaceutica Ag
Publication of BR0107764A publication Critical patent/BR0107764A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçõES DE PEPTìDEO CìCLICO NASALMENTE ADMINISTRáVEIS". A presente invenção refere-se a uma composição nasalmente administrável de um peptídeo cíclico fisiologicamente ativo e seus sais farmaceuticamente aceitáveis, a qual é preparada dispersando homogeneamente um peptídeo cíclico fisiologicamente ativo tal como peptídeos cíclicos antifúngicos (aerotricinas, análogos de equinocandina, análogos de pneumocandina e auroebacidinas), peptídeos cíclicos antibacterianos (por exemplo, vancomicina, daptomicina), ciclosporina A, lanreotídeo, vapreotídeo, antagonista de vasopressina (US 5.095.003) e eptifibatídeo em um único veículo, isto é, um veículo em pó ou cristalino fisiologicamente aceitável contendo um veículo de metal de polivalência insolúvel em água, ou veículo orgânico tendo um tamanho de partícula médio de 20 a 500 <109>m, na presença ou ausência de um intensificador de absorção e adsorvendo homogeneamente no veículo, e seu uso para tratamento terapêutico de doença tal como infecções fúngicas sistêmicas através de administração intranasal. A composição pode ser nasalmente administrada na forma de pó.
BR0107764-3A 2000-01-20 2001-01-09 Composições de peptìdeo cìclico nasalmente administráveis BR0107764A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00101057 2000-01-20
PCT/EP2001/000163 WO2001052894A2 (en) 2000-01-20 2001-01-09 Nasally administrable cyclic peptide compositions

Publications (1)

Publication Number Publication Date
BR0107764A true BR0107764A (pt) 2002-11-12

Family

ID=8167663

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0107764-3A BR0107764A (pt) 2000-01-20 2001-01-09 Composições de peptìdeo cìclico nasalmente administráveis

Country Status (16)

Country Link
US (1) US20010038824A1 (pt)
EP (1) EP1251827B1 (pt)
JP (1) JP2003535042A (pt)
KR (1) KR20020070346A (pt)
CN (1) CN1406124A (pt)
AR (1) AR027244A1 (pt)
AT (1) ATE267582T1 (pt)
AU (1) AU3728001A (pt)
BR (1) BR0107764A (pt)
CA (1) CA2396381A1 (pt)
DE (1) DE60103504T2 (pt)
DK (1) DK1251827T3 (pt)
ES (1) ES2220724T3 (pt)
MX (1) MXPA02007052A (pt)
WO (1) WO2001052894A2 (pt)
ZA (1) ZA200205240B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60110209T2 (de) * 2000-01-17 2006-05-11 Basilea Pharmaceutica Ag Aerothricin analoge, deren herstellung und verwendung
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
TWI324934B (en) * 2001-08-28 2010-05-21 Schering Corp Pharmaceutical compositions for the treatment of asthma
US20050014681A1 (en) * 2001-11-26 2005-01-20 Yoshiharu Minamitake Medicinal compositions for nasal absorption
US7047259B1 (en) 2002-06-25 2006-05-16 Oracle International Corporation Rich cross object navigation in mobile applications
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
PT1587514E (pt) * 2003-01-31 2006-09-29 Orexo Ab Composicao farmaceutica de accao rapida
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
EP1607117A4 (en) 2003-03-27 2007-10-24 Bioactis Ltd APPLICATOR FOR POWDER MEDICATION IN THE NOSE CAVE
US8673360B2 (en) * 2004-08-10 2014-03-18 Shin Nippon Biomedical Laboratories, Ltd. Compositions that enable rapid-acting and highly absorptive intranasal administration
WO2007134241A2 (en) * 2006-05-11 2007-11-22 University Of Maryland Baltimore Nasal delivery of therapeutic agents using tight junction agonists
JP5415769B2 (ja) * 2006-12-26 2014-02-12 株式会社新日本科学 経鼻投与用製剤
CA2693377A1 (en) 2007-07-21 2009-01-29 Albany Molecular Research, Inc. 5-pyridinone substituted indazoles
US20090324569A1 (en) 2007-11-21 2009-12-31 Decode Genetics Ehf Biaryl pde4 inhibitors for treating inflammatory, cardiovascular and cns disorders
KR101614723B1 (ko) 2008-01-11 2016-04-22 알바니 몰레큘라 리써치, 인크. Ｍｃｈ 길항물질로서 (1-아지논)-치환된 피리도인돌
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
WO2010084499A2 (en) 2009-01-26 2010-07-29 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds
US9101539B2 (en) * 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
GB2472327B (en) * 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
US8802622B2 (en) 2010-03-19 2014-08-12 Daiichi Sankyo Company, Limited Composition for nasal administration and method for preparing same
CN102746384B (zh) * 2011-04-22 2016-01-20 上海天伟生物制药有限公司 一种高纯度的卡泊芬净或其盐及其制备方法和用途
LT2922530T (lt) 2012-11-20 2017-01-25 Fresenius Kabi Usa, Llc Kaspofungino acetato kompozicijos
US10905744B2 (en) 2015-10-07 2021-02-02 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
US11174288B2 (en) 2016-12-06 2021-11-16 Northeastern University Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
CA3093340A1 (en) 2018-03-20 2019-09-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
WO2020049505A1 (en) 2018-09-06 2020-03-12 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
AU2019419414A1 (en) 2018-12-31 2023-04-06 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CN112852908B (zh) * 2021-01-11 2023-05-19 青海省农林科学院 一种具有除草作用的短梗霉素及其制备方法、测定方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2750090A1 (de) * 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
US5331089A (en) * 1988-03-25 1994-07-19 Merck Sharpe & Dohme, Ltd. Peptides useful as tachykinin agonists
US5202309A (en) * 1989-06-30 1993-04-13 Merck & Co., Inc. Antibiotic cyclopeptide fermentation product
US5051400A (en) * 1990-06-28 1991-09-24 Smithkline Beecham Corporation Method of treating nausea and emesis related to motion sickness with vasopressin antagonists
ES2088160T3 (es) * 1991-04-19 1996-08-01 Nexstar Pharmaceuticals Inc Formulacion y proceso quimicos.
KR940006601A (ko) * 1992-09-12 1994-04-25 야나가와 히로미 생리활성 펩티드 조성물
FI92334C (fi) * 1992-12-30 1994-10-25 Leiras Oy Menetelmä syklosporiinien tuottamiseksi ja menetelmässä käytettävä uusi Tolypocladium-kanta
KR0146671B1 (ko) * 1994-02-25 1998-08-17 김충환 사이클로스포린-함유 분말 조성물
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
DE69615535T2 (de) * 1995-01-26 2002-05-02 Merck & Co Inc Neue fungizide cyclohexapeptide
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
US5696084A (en) * 1996-08-16 1997-12-09 Abbott Laboratories Amino-lipopetide antifungal agents
US5830855A (en) * 1996-09-12 1998-11-03 Utah State University Lipodepsipeptides as antifungal and fungicidal agents
US6165484A (en) * 1997-08-26 2000-12-26 Wake Forest University EDTA and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
MA26663A1 (fr) * 1998-07-23 2004-12-20 Hoffmann La Roche Nouvelles aerothricines et leurs applications antifongiques

Also Published As

Publication number Publication date
DE60103504T2 (de) 2005-06-09
KR20020070346A (ko) 2002-09-05
US20010038824A1 (en) 2001-11-08
CA2396381A1 (en) 2001-07-26
WO2001052894A3 (en) 2002-01-31
JP2003535042A (ja) 2003-11-25
AR027244A1 (es) 2003-03-19
CN1406124A (zh) 2003-03-26
EP1251827A2 (en) 2002-10-30
ATE267582T1 (de) 2004-06-15
DE60103504D1 (de) 2004-07-01
ZA200205240B (en) 2003-09-29
WO2001052894A2 (en) 2001-07-26
ES2220724T3 (es) 2004-12-16
AU3728001A (en) 2001-07-31
DK1251827T3 (da) 2004-09-27
EP1251827B1 (en) 2004-05-26
MXPA02007052A (es) 2002-12-13

Similar Documents

Publication Publication Date Title
BR0107764A (pt) Composições de peptìdeo cìclico nasalmente administráveis
US5902789A (en) Nasal administration of drugs
ES2630106T3 (es) Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
EP1115417B1 (en) Use of daptomycin
US20060228385A1 (en) Sustained release of microcrystalline peptide suspensions
CN1109558C (zh) 稳定的药用肽组合物
JP2022130627A5 (pt)
KR20070116181A (ko) 보존 제약 제형
EA200501001A1 (ru) Фармацевтический состав с нерастворимым активным агентом
US20220289794A1 (en) Synthetic antimicrobial peptides
WO1997018827A1 (en) Compositions and methods for the prevention and treatment of oral mucositis
Kamaluddin et al. Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies
US8420130B1 (en) Pharmaceutical formulation of a didemnin compound
WO2016059592A1 (en) Stable injectable composition of peptide drugs and process for its preparation
NZ516108A (en) Ophthalmic composition containing ketotifen and a non-ionic tonicity agent
US20150246093A1 (en) Oral formulations of angiotensin
KR970004039B1 (ko) 점막 투여시 흡수 촉진제로서의 시클릭 펩티드
US20130196912A1 (en) Beta thymosin fragments
WO2022200224A1 (en) Compounds for use in the treatment of sinusitis, pneumonia or otitis
ES2283820T3 (es) Preparados para la aplicacion intranasal de antagonistas de cgrp seleccionados, derivados de aminoacidos asi como procedimiento para su obtencion.
US20210060121A1 (en) Novel antibiotics and methods of using them
WO2005019457A3 (en) NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY
US20240108735A1 (en) Methods and compositions for treating covid infections
DK2174652T3 (en) Oral, pharmaceutical desmopressin composition
Baamonde et al. Effects of intraplantar morphine in the mouse formalin test

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1963 DE 19.08.2008.